Arthur Chan

Arthur has over 18 years of pharmaceutical and medical device experience and came to Tarsus from Novartis where he was Lead Medical Director, overseeing the anterior segment medical affairs team and their dry eye and refractive products, including Xiidra®. Prior to this role, he was the Executive Director of Medical Science Liaison (MSL) capabilities, managing MSL training and medical/legal/regulatory review across all of Novartis’ franchises. Previously, as Head of Medical Science at Alcon, Arthur built and led the company’s first surgical MSL team, supporting Alcon’s surgical suite, intraocular lenses, and the entire cataract, refractive, glaucoma and retina portfolio. Arthur began his career at Insightec, a start-up company where he was part of a team that managed the clinical trials, physician training, and PMA process that led to the world’s first FDA-approved, image-guided focused ultrasound surgery device. He transitioned into eye care when he joined Bausch and Lomb as a Medical Liaison, launching Lotemax Gel and Prolensa.

Arthur received his BS in mechanical engineering from the University of Alberta, a PhD in biomedical engineering from the University of Washington, and an executive MBA with a specialty in pharmaceutical and healthcare marketing from St. Joseph’s University. He holds multiple patents, is a graduate of the University of Washington’s Technology Entrepreneurship Program, and was a WRF Capital Gates Foundation fellow involved with turning UW technology into start-up companies. He is currently an adjunct professor at St. Joseph’s University’s Haub School of Business and is on the advisory boards of the MSL Society and Fierce Pharma’s Medical Affairs Summit. Arthur is the 2021 recipient of the Ophthalmic World Leaders’ Catalyst Award, a peer recognition given to an individual that contributed significantly to helping others advance their careers in eye care while advancing diversity, equity, and inclusion in the field.